Clinical Trial


A Study Evaluating Safety and Tolerability of YM150 Compared to Warfarin in Subjects With Atrial Fibrillation


Brief description

The purpose of this study is to investigate the optimal daily dose and dose regimen of YM150 in subjects with non-valvular atrial fibrillation (NVAF), primarily based on safety and tolerability data.

Keywords

  •   Atrial Fibrillation

Sponsored By

Astellas Pharma Inc

Unique Study ID

NCT00938730

Investigators and Research Sites Near You - Found( 3 )

No Investigator Listed

Foundation for Innovative New Diagnostics, Switzerland
Pune, India
Distance from Current Trial is 0 miles

No Investigator Listed

Novartis
411013, Pune, Maharashtra, India
Distance from Current Trial is 0 miles

Dr Ninad Naik, MD(Ayurveda)

The Herb, Inc
411019, Pune, Maharashtra, India
Distance from Current Trial is 0 miles
View All